Random C-Peptide — Diabetes Classification
Fasting C-peptide to fasting glucose ratio helps distinguish type 1 from type 2 diabetes and assesses residual beta-cell function. Low ratio suggests type 1 or insulin deficiency; high ratio suggests type 2 or insulin resistance.
Score interpretation
Below 0.2 nmol/L (200 pmol/L): severe insulin deficiency, consistent with type 1 diabetes (Exeter; ADA/EASD 2021).
→ Treat as insulin-deficient.
Intermediate result; interpret with the clinical picture and islet autoantibodies.
→ Consider autoantibodies; specialist review.
Above 0.6 nmol/L (600 pmol/L) non-fasting is strongly suggestive of type 2 diabetes (ADA/EASD 2021).
→ Review classification; consider MODY in young-onset diabetes.
Interpretation bands for the C-peptide. Apply clinical judgement and local guidance.
References
- Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017;60(5):769–777.
Related
Curated clinical cross-links plus same-class fallbacks.
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Noradrenaline (Norepinephrine) · Vasopressor (Alpha-1 and Beta-1 Agonist)
- Dobutamine (ICU — Inotrope) · Inotrope (Beta-1 Agonist)
- Labetalol (IV — Hypertensive Emergency) · Combined Alpha-1 and Beta-Adrenergic Blocker
- Ephedrine hydrochloride · Mixed alpha/beta-adrenergic agonist (vasopressor)
- Sotalol · Antiarrhythmic
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.